Speakers - Melbourne Symposium 2018

Inhee Choi, RPh, PhD

Senior Researcher, Bioinformatics Group

Institut Pasteur Korea (IPK)

Inhee Choi is highly experienced in computational aided drug design with a pharmacist background. She has a PhD in computational aided drug design from College of Pharmacy, Ewha Womans University in Korea and completed her postdoctoral training at the National Institute of Health (NIH), Maryland, USA. Inhee joined Institut Pasteur Korea (IPK) in 2010 upon returning to Korea. She continues to be actively involved in various bio-cheminformatics research projects. She manages and organises chemical and biological data information within her groups in the graduate school, NIH, and IPK.
 

Bradley Doak, PhD

Postdoctoral Research Scientist

Monash University

Brad completed a PhD in Synthetic Medicinal Chemistry at MIPS under the supervision of Martin Scanlon and Jamie Simpson in the area of fragment-based drug design. He then undertook postdoctoral training with Jan Kihlberg at Uppsala University, Sweden, looking at drug discovery beyond the rule of 5 with particular attention on macrocycles. Brad then returned to Monash University with the formation of the Monash Fragment Platform to continue working on fragment-based drug design, particularly early hit to lead development. Brad’s interests include medicinal chemistry and chemoinformatics in fragment development, particularly in the development of libraries. Brad’s talk will focus on the work currently undertaken on the development and design of libraries for early stages of development in fragment-based drug design, focusing on the use of designed generic reagent libraries for development when little to no structural information is available.
 

Wolfgang Jarolimek

Head of Drug Discovery

Pharmaxis

Wolfgang joined Pharmaxis in September 2010 as Manager in vitro Pharmacology and was appointed Head Drug Discovery in August 2012.
He has more than 15 years’ experience in pharmaceutical drug discovery and has published more than 30 peer reviewed articles. From 2002 to 2010 Wolfgang was Director of Assay Development and Compound Profiling at the GlaxoSmithKline Center of Excellence in Drug Discovery in Verona, Italy. In addition to chairing early drug discovery efforts locally he also had global responsibilities for ion channel screening and implementing safety-related screening. From 1998 to 2002 he worked at the Neuroscience Center of Merck, Sharp and Dohme in Harlow, England, as Senior Research Scientist in the electrophysiology group. Wolfgang previously spent 8 years as post-doc at the Max-Plank Institute in Munich, Germany; Baylor College of Medicine, Houston, Texas; Rammelkamp Center, Cleveland Ohio; and University of Heidelberg, Germany.
Wolfgang holds a BSc in Pharmacy and a PhD from the University of Saarbrücken, Germany. In 1997 he became Assistant Professor in Physiology at the University of Heidelberg, Germany.
 

Guilhem Morra

Science Systems Analyst

Plant and Food Research

I have a background in heterogeneous catalysis and high throughput screening. I hold an MSc from École Centrale de Lyon and a PhD in Chemistry from Université Claude Bernard in France. I have worked for 8 years with Johnson Matthey (UK) where I was helping our Teesside research centre with scientific data management. I have started with Plant & Food Research, New Zealand biggest Crown Research Institute in November 2016 to manage the implementation of Dotmatics across the institute.
 

Rebecca Moss

Manager, Research Technologies

Cancer Therapeutics CRC (Ctx)

Rebecca has a background in high throughput screening and data management. She holds a BSc in Applied Biology/Biotechnology (Hons) from RMIT University Melbourne. Rebecca has worked at the WEHI for 16 years and has been involved with Cancer Therapeutics (CTx) since 2008 when an electronic laboratory notebook was first introduced.

Rebecca is responsible for developing and maintaining the CTx eResearch platform, which includes the infrastructure, data systems and the applications. The eResearch Platform hosts applications such as Atlassian, SharePoint and Dotmatics. These tools facilitate the analysis and reporting of research data generated at all stages of the drug discovery pipeline.

Rebecca’s talk will focus on CTx's journey to Dotmatics and will highlight current workflows and customised features that have become essential to the data management of their successful drug discovery program.
 

Grant Stuchbury

Senior Biologist

Qeddi

With a background in neurobiology and oncology, I have been involved in small molecule drug discovery for the past 8 years. My first post-doctoral position was at Griffith University, as part of the Cancer Therapeutics CRC (CTx), where I developed and performed high throughput screening campaigns, with a focus on high content imaging. In my current role as Senior Biologist at QEDDI, I established the biology laboratory and now lead the team in designing, developing and validating robust, reliable and relevant biological assays for both high throughput screening and ongoing small molecule development.
 

Request a demonstration or
ask us a question